• Defining Retroviruses
• 38 min
  1. An introduction to retroviruses: replication strategy and genetics

  • Dr. Jonathan Stoye
• 45 min
  2. Bovine leukemia virus

  • Prof. Arsene Burny
  • Dr. Lucas Willems
• The First Human Retroviruses
• 65 min
  3. The discovery of human retroviruses and how they cause disease

  • Prof. Robert Gallo
• HIV - Peculiarities of its Genome
• 11 min
  4. HIV: peculiarities of its genome

  • Dr. George Pavlakis
• HIV Transmission, Epidemiology and Public Health/Prevention Issues
• 42 min
  5. HIV/AIDS epidemiology, transmission, and risk factors

  • Prof. William Blattner
• 55 min
  6. HIV prevention and public health issues: a global perspective

  • Prof. Sten H. Vermund
• How HIV causes AIDS
• 35 min
  7. How HIV causes disease 1: identification and characterization of HIV

  • Prof. Bruce Walker
• 43 min
  8. How HIV causes disease 2: immune responses to HIV infection

  • Prof. Bruce Walker
• HIV Therapy - Now and the Future
• 34 min
  9. HIV therapy: taking advantage of progress

  • Prof. Paul Volberding
• 39 min
  10. HIV cure: harnessing innate and adaptive strategies

  • Prof. Luis Montaner
• Archived Lectures *These may not cover the latest advances in the field
• 36 min
  11. The first human retroviruses: the human T lymphotropic viruses (HTLVs)

  • Prof. William Hall
• 59 min
  12. HIV preventive vaccines

  • Prof. Andrew McMichael
• 31 min
  13. HIV/AIDS in the developing world: what can we do?

  • Dr. Joseph O'Neill
• 54 min
  14. Human T-cell leukemia virus type 1 (HTLV-1) and adult T-cell leukemia: insights into cellular transformation

  • Prof. Kuan-Teh Jeang
• 41 min
  15. Antiretroviral therapy 2007, new concepts and lessons learned

  • Prof. Robert Redfield
• 29 min
  16. What to do in therapy in the face of HIV drug resistance?

  • Prof. Mark Wainberg
• 42 min
  17. Viral reservoirs, latency and mechanisms of HIV persistence

  • Prof. Robert Siliciano
• 28 min
  18. HIV preintegration complexes

  • Prof. Lee Ratner
• 30 min
  19. The discovery of ATL field expansion in 40 yrs

  • Prof. Junji Yodoi

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. HIV distribution
3. HIV in Africa
4. HIV particle
5. HIV infection timeline
6. Innate immunity - first response to HIV
7. T cell responses
8. CD4 T cells are susceptible to HIV infection
9. First adaptive immune responses
10. Immune responses during HIV infection
11. Evidence that CD8 T cells control HIV infection
12. Viremia control: normal vs. CD8-depletion
13. Acute HIV infection
14. HIV escape mutations
15. Immune control of HIV
16. HLA types and hazard for disease progression
17. CD8 T cells control HIV infection - summary
18. Antibody response to HIV-2
19. Viral membrane fusion
20. HIV envelope structural changes upon binding
21. Generation of neutralising antibodies
22. Vaccines
23. Antibody vaccines for HIV
24. T cell vaccine control of HIV
25. Protection by CD8 T cell-inducing vaccines
26. HIVA DNA/MVA immunization in mice\macaques
27. HIVA DNA + MVA in humans
28. DNA\MVA stimulated CD4 Th1 responses
29. MVA.HIVA boosts HIV-1-specific CD8 T cells
30. Current T cell vaccines for HIV
31. Phase IIB trials - Merck rAd5 vaccine
32. The problem of HIV variability
33. Illustration of the HIV variability problem
34. Only 1/3 of CTL epitope variants recognized
35. Ways to tackle HIV-1 diversity
36. Conclusions
37. Acknowledgements

Topics Covered

• HIV distribution
• HIV in Africa
• HIV particle
• T-cell responses
• CD4 T-cells susceptible to HIV infection
• CD8 T-cells control HIV infection
• Acute HIV infection
• HIV escape mutations when CTL response focused on dominant epitope
• Immune control of HIV
• Antibody response to HIV-1
• Viral membrane fusion
• 5 broadly neutralizing antibodies
• Antibody vaccines for HIV
• T-cell vaccine control of HIV
• CD8+ T-cell inducing vaccines partly protect against SIV/SHIV challenge
• HIVA DNA/MVA immunization in mice and macaques
• HIVA DNA + MVA in humans
• MVA.HIVA boosts HIV-1-specific CD8 T-cells in HIV+ donors on ART
• Current T-cell vaccines for HIV
• Phase IIB trials
• Merck rAd5 vaccine
• The problem of HIV variability
• Ways to tackle HIV-1 diversity

Links

Series:

• Retroviruses

Categories:

• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases
• Vaccines

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Andrew McMichael has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.